A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease (aGVHD) Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant (Allo HSCT) Patients
Phase of Trial: Phase I
Latest Information Update: 26 Mar 2018
Price : $35 *
At a glance
- Drugs Bortezomib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 20 Mar 2018 Status changed from recruiting to completed.
- 28 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 01 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016.